Magenta Therapeutics Announces $ 86.4 Million Common Stock Investment from Multiple Investors

CAMBRIDGE, Mass .– (COMMERCIAL THREAD) – Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing new drugs to bring the healing power of stem cell transplants to more patients, announced that it had agreed to sell approximately 9,600,000 common shares to certain institutional investors in a private placement. Magenta expects the aggregate gross proceeds from the offering to be $ 86.4 million, before deducting the estimated offering fees payable by the Company, based on the offering price of $ 9.00 per share. The fund syndicate includes Deep Track Capital, LP, TCG X, Great Point Partners, LLC, OrbiMed and Janus Henderson Investors. The closing is expected to take place on May 14, 2021, subject to customary closing conditions. Magenta intends to use the net proceeds of the offering for general corporate purposes and working capital.

The securities are sold by private placement and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. The Company has agreed to file a resale registration statement with the Securities and Exchange Commission (the “SEC”), for the purpose of registering the resale of Common Shares issued or issuable under the Offer.

Important information

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no offer or sale of such securities in any State or other jurisdiction in which such an offer , solicitation or sale would be illegal prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer of securities under the resale registration statement will only be made by means of a prospectus.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing drugs to bring the healing power of stem cell transplants to a greater number of patients with blood cancers, genetic diseases and autoimmune diseases. Magenta combines leadership in stem cell biology and biotherapeutic development with clinical and regulatory expertise, a unique business model and extensive networks in the stem cell transplant community to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit

Follow Magenta on Twitter: @magentatx.

Forward-looking statements

This press release contains forward-looking statements that are made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The use of words such as “anticipate”, “believe”, “continue”, ” could “,” “strive”, “estimate”, “expect”, “anticipate”, “intend”, “may”, “could”, “plan”, “potential”, ” anticipate, ”“ plan ”,“ seek ”,“ should, ”“ target ”,“ will ”or“ would ”or the negative of these words or other similar expressions may be used to identify forward-looking statements. All forward-looking statements included in this press release, such as statements regarding the expected time of closing of the private placement and the intended use of the proceeds of the private placement, are based on the current expectations and beliefs of management and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by the forward-looking statements contained in this press release, including, without limitation, uncertainties relating to market conditions and the completion of the offering on the terms expected, if at all. These and other risks and uncertainties are described in more detail in the section entitled “Risk Factors” of Magenta’s annual report on Form 10-K filed on March 3, 2021, as updated by its quarterly reports on Form 10-Q and its other documents. done with the SEC from time to time. Although Magenta’s forward-looking statements reflect the good faith judgment of its management, such statements are based only on facts and factors currently known to Magenta. Therefore, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Magenta assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Source link

Comments are closed.